<DOC>
	<DOC>NCT02426099</DOC>
	<brief_summary>This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.</brief_summary>
	<brief_title>Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Resistant hypertension Diabetes mellitus T2DM with overt acute/chronic complications, serum potassium ≥ 5.5 mmol/l, estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease formula ≤ 30 ml/min/1.73m² of body weight, absolute contraindication to any of the drug regimen of the trial, and current aldosterone antagonist treatment or cessation within the last 15 months</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Resistant hypertension</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>African</keyword>
</DOC>